Aurora Cannabis posts record $288.6M annual revenue, 18% growth, boosts EBITDA 32%, expands EU capacity

Aurora Cannabis reported a record $288.6 million in global medical cannabis net revenue for fiscal year 2026, marking an 18% year-over-year increase. Adjusted EBITDA also reached a record $53.8 million, up 32% from the previous year, driven by strong growth in Europe and strategic acquisitions like Safari Flower Company, which adds critical EU-GMP certified production capacity. The company is focusing on expanding its profitable international medical cannabis markets while exiting lower-margin consumer and plant propagation businesses. For fiscal 2027, Aurora expects revenue to stabilize with growth in Europe offsetting Canadian pricing pressures, maintaining strong margins and steady operating expenses.